TIGIT/PD-L1 inhibitors are clinically cooperative in the treatment of NSCLC AstraZenecon

Immuno-checkpoint protein inhibitors, represented by PD-1/PD-L1 inhibitors, have revolutionized cancer treatment, but there are still many cancer patients who do not respond to them.
, one of the important directions of immuno-oncology research is to build a combination therapy based on PD-1/PD-L1 inhibitors to expand the efficacy of immunotherapy and benefit the patient population.
, TIGIT is a high-profile target, and its full name is T cell immunoglobulin and ITIM domain protein (T cell immunoreceptor with Ig and ITIM domains).
it is an inhibitory subject expressed on the surface of many types of immune cells.
-mediated signaling path through TIGIT inhibits the role of a range of cancer-fighting immune cells.
developed by Marcus, domvanalimab (AB154) is a monoclonal antibody targeting TIGIT that blocks TIGIT activity at the namor level, thereby blocking immunosuppression and increasing immune activity.
domvanalimab has shown good safety in clinical trials and is currently being tested in Phase 2 clinical trials.
the mechanism of effect of TIGIT inhibitors (Image Source: Arcus) The results of phase 3 clinical trials of PACIFIC 3, recently published at the annual meeting of the European Society of Oncology (ESMO), show that in patients with Stage III NSCLC who cannot be surgically removed, the survival of patients using Immunofinzi therapy after receiving chemical radiotherapy (CRT) significantly improved their survival.
estimates that 50 percent of patients survive for four years, compared with 36 percent in the CRT group alone, 35 percent in those without disease progression after four years, and 20 percent in the CRT group alone.
resources: s1? Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus's Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC. Retrieved October 29, 2020, from